ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 831

Mycophenolate Decreases the Frequency of Endoscopic Therapy for Gastric Antral Vascular Ectasia in Patients with Systemic Sclerosis

Tiffany Lin1, James Bena2, Shannon Morrison2 and Soumya Chatterjee3, 1Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, 2Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, 3Cleveland Clinic Foundation, Cleveland, OH

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Anemia, gastrointestinal complications, immunosuppressants, scleroderma and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:
Gastric antral vascular
ectasia (GAVE) is an increasingly recognized cause of upper gastrointestinal
bleeding in patients with systemic sclerosis (SSc).  These patients may
require frequent interventions, which negatively impact quality of life. 
There is currently no defined role for immunosuppressive therapy in the
treatment of GAVE.  The goal of this study was to determine whether
immunosuppressive therapy, used for any indication, also has a role in reducing
the frequency of interventions for GAVE in patients with SSc. 

Methods:
A retrospective chart review
was performed on patients that were seen within the past 10 years at our
institution who had SSc complicated by GAVE.  Data on demographic and
clinical characteristics were collected.  Types of immunosuppressive
therapies and the time periods used were recorded.  Intervention rates
(hospitalizations, blood transfusions, and endoscopic therapies) were compared
using repeated measures Poisson regression models to account for the different
medication periods for each patient.

Results:
Forty-eight patients with
SSc complicated by GAVE were identified (Table 1).  Twenty-nine received
immunosuppressive therapy.  Those who received immunosuppressive therapy
had anti-centromere antibodies less often than those who did not receive
therapy (17.2% versus 52.6%, p=0.010).  Other patient characteristics were
not significantly different between the two groups.  The most commonly used
therapy was mycophenolate (n=14), followed by glucocorticoids (n=11),
hydroxychloroquine (n=7), cyclophosphamide (n=4), intravenous immunoglobulin
(n=3), methotrexate (n=3), and azathioprine (n=1).   When receiving
immunosuppressive therapy, patients required therapeutic endoscopies less
frequently (0.51/year versus 1.37/year, p=0.009) (Table 2).  This decrease
in frequency was more pronounced with mycophenolate in particular (0.25/year
versus 1.37/year, p=0.013).  There were no significant differences in
hospitalization or blood transfusion frequencies. 

Conclusion: Mycophenolate may have the potential to alter
the course of disease in patients who have GAVE associated with SSc, and can be
considered in those who require frequent therapeutic endoscopies.  Further
studies are needed to confirm these findings.


Disclosure: T. Lin, None; J. Bena, None; S. Morrison, None; S. Chatterjee, None.

To cite this abstract in AMA style:

Lin T, Bena J, Morrison S, Chatterjee S. Mycophenolate Decreases the Frequency of Endoscopic Therapy for Gastric Antral Vascular Ectasia in Patients with Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/mycophenolate-decreases-the-frequency-of-endoscopic-therapy-for-gastric-antral-vascular-ectasia-in-patients-with-systemic-sclerosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mycophenolate-decreases-the-frequency-of-endoscopic-therapy-for-gastric-antral-vascular-ectasia-in-patients-with-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology